AR042670A1 - Uso del abridor del canal de cloruro para preparar un compuesto farmaceutico para tratar el malestar abdominal - Google Patents

Uso del abridor del canal de cloruro para preparar un compuesto farmaceutico para tratar el malestar abdominal

Info

Publication number
AR042670A1
AR042670A1 ARP030104848A ARP030104848A AR042670A1 AR 042670 A1 AR042670 A1 AR 042670A1 AR P030104848 A ARP030104848 A AR P030104848A AR P030104848 A ARP030104848 A AR P030104848A AR 042670 A1 AR042670 A1 AR 042670A1
Authority
AR
Argentina
Prior art keywords
hydroxy
group
halogen
heterocyclic
chloride channel
Prior art date
Application number
ARP030104848A
Other languages
English (en)
Inventor
R Ueno
S Kuno
Original Assignee
Sucampo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32717850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR042670(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Pharmaceuticals Inc filed Critical Sucampo Pharmaceuticals Inc
Publication of AR042670A1 publication Critical patent/AR042670A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/56—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Uso de un abridor del canal de cloruro, en especial un compuesto de prostaglandina, para el tratamiento de malestar abdominal. Uso de un abridor del canal de cloruro, en especial un compuesto de prostaglandina, para el tratamiento de trastornos gastrointestinales funcionales. Reivindicación 2: El uso de acuerdo con la reivindicación 1, donde dicho compuesto de prostaglandina es el compuesto representado por la fórmula general (1), donde: L, M y N son átomo de hidrógeno, hidroxi, átomo de halógeno, alquilo inferior, hidroxialquilo (inferior), alcanoiloxi inferior u oxo, donde al menos una de L y M es un grupo diferente de hidrógeno, y el anillo de cinco miembros puede tener al menos un enlace doble; A es -CH3 o -CH2OH, -COCH2OH, -COOH o uno de sus derivados funcionales; B es un enlace simple, -CH2-CH2-, -CH=CH-, -C=C-, -CH2-CH2-CH2-, -CH=CH-CH2-, -CH2-CH=CH-, -C:::C-CH2- o -CH2-C:::C-; Z es un resto de grupo de fórmula (2) o un enlace simple, donde: R4 y R5 son hidrógeno, hidroxi, halógeno, alquilo inferior, alcoxi inferior o hidroxialquilo (inferior), donde R4 y R5 no son hidroxi y alcoxi inferior al mismo tiempo; R1 es un residuo hidrocarbonado alifático inferior o medio bivalente saturado o insaturado que está insustituido o sustituido con halógeno, alquilo, hidroxi, oxo, arilo o grupo heterocíclico, y al menos uno de los átomos de carbono en el hidrocarburo alifático está opcionalmente sustituido con oxígeno, nitrógeno o azufre; y Ra es un residuo hidrocarbonado alifático inferior o medio saturado o insaturado que está insustituido o sustituido con halógeno, oxo, hidroxi, alquilo inferior, alcoxi inferior, alcanoiloxi inferior, cicloalquilo (inferior), cicloalquiloxi (inferior), arilo, ariloxi, grupo heterocíclico o grupo heterocíclico-oxi; alcoxi inferior; alcanoiloxi inferior; cicloalquilo (inferior); cicloalquiloxi (inferior); arilo; ariloxi; grupo heterocíclico; grupo heterocíclico-oxi.
ARP030104848A 2002-12-27 2003-12-29 Uso del abridor del canal de cloruro para preparar un compuesto farmaceutico para tratar el malestar abdominal AR042670A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43646302P 2002-12-27 2002-12-27
US43646202P 2002-12-27 2002-12-27

Publications (1)

Publication Number Publication Date
AR042670A1 true AR042670A1 (es) 2005-06-29

Family

ID=32717850

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104848A AR042670A1 (es) 2002-12-27 2003-12-29 Uso del abridor del canal de cloruro para preparar un compuesto farmaceutico para tratar el malestar abdominal

Country Status (15)

Country Link
US (3) US7795312B2 (es)
EP (2) EP2281564A3 (es)
JP (2) JP4889219B2 (es)
KR (2) KR101164838B1 (es)
CN (1) CN1753680B (es)
AR (1) AR042670A1 (es)
AU (1) AU2003292556B2 (es)
BR (1) BRPI0317740B8 (es)
CA (1) CA2510051C (es)
ES (1) ES2591252T3 (es)
MX (1) MXPA05006981A (es)
NO (1) NO335441B1 (es)
NZ (1) NZ541110A (es)
TW (1) TWI336254B (es)
WO (1) WO2004060377A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331920B (en) * 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
CA2502439C (en) * 2002-10-23 2011-11-22 Sucampo Ag Prostaglandin compounds for the treatment of obesity
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI387454B (zh) * 2004-09-02 2013-03-01 Sucampo Ag 治療胃腸道疾病之方法及組成物
CN101180096B (zh) * 2005-03-21 2015-04-22 苏坎波公司 用于治疗粘膜疾病的方法和组合物
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
US8962688B2 (en) * 2005-04-12 2015-02-24 Sucampo Ag Method for the treatment of gastrointestinal disorders
US7868045B2 (en) 2006-09-06 2011-01-11 Sucampo Ag Method for promoting gastrointestinal bicarbonate secretion
WO2008108322A2 (en) * 2007-02-27 2008-09-12 Sucampo Ag Composition and method for protecting mitochondria
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
CN104958298A (zh) * 2009-09-18 2015-10-07 阿得罗公司 阿片样受体拮抗剂用于胃肠道疾病的用途
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
EP2841065A4 (en) * 2012-04-23 2015-09-16 Sucampo Ag METHOD FOR TREATING IRRITATION SYNDROME WITH RUNNING
CA2888021A1 (en) 2012-10-15 2014-04-24 Epizyme, Inc. Substituted n-((2-oxo-1,2-dihydropyridin-3-yl)-methyl)-benzamide compounds and their use in the treatment of ezh2-mediated disorders
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1581886A (en) * 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2039420C (en) 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
CA2041417C (en) 1990-05-01 2002-05-21 Ryuji Ueno Treatment of pancreatic disease with 15-keto-prostaglandin compounds
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
DE69714698T2 (de) 1996-06-10 2002-12-05 Sucampo Ag Endothelin-antagonisten
US6046239A (en) * 1997-08-05 2000-04-04 American Home Products Corporation Anthranilic acid analogs
US6197821B1 (en) * 1997-11-28 2001-03-06 R-Tech Ueno, Ltd. Endothelin antagonist
US6492417B1 (en) * 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
ATE267189T1 (de) 1999-10-15 2004-06-15 Sucampo Ag Bizyclische verbindungen zusammenstellung und verfahren zu ihrer stabilisierung
KR100874626B1 (ko) * 2000-04-06 2008-12-17 수캄포 아게 담즙 분비 촉진 조성물
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
WO2002094274A1 (en) 2001-05-18 2002-11-28 Sucampo Ag Cathartic composition
JP4786866B2 (ja) 2001-08-31 2011-10-05 スキャンポ・アーゲー クロライドチャンネルオープナーとしてのプロスタグランジンアナログ
TWI331920B (en) * 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel

Also Published As

Publication number Publication date
MXPA05006981A (es) 2005-12-14
US20040138308A1 (en) 2004-07-15
US20130217770A1 (en) 2013-08-22
TWI336254B (en) 2011-01-21
KR20120045051A (ko) 2012-05-08
JP2012031202A (ja) 2012-02-16
NZ541110A (en) 2008-11-28
CN1753680A (zh) 2006-03-29
EP1575596B1 (en) 2016-06-22
NO335441B1 (no) 2014-12-15
KR20050086950A (ko) 2005-08-30
ES2591252T3 (es) 2016-11-25
EP2281564A2 (en) 2011-02-09
WO2004060377A1 (en) 2004-07-22
BRPI0317740B8 (pt) 2021-05-25
AU2003292556A1 (en) 2004-07-29
US7795312B2 (en) 2010-09-14
NO20053623D0 (no) 2005-07-26
JP4889219B2 (ja) 2012-03-07
TW200418491A (en) 2004-10-01
CN1753680B (zh) 2010-12-08
BRPI0317740B1 (pt) 2018-09-18
JP2006513232A (ja) 2006-04-20
CA2510051A1 (en) 2004-07-22
NO20053623L (no) 2005-09-26
EP2281564A3 (en) 2012-09-05
KR101164838B1 (ko) 2012-07-11
BR0317740A (pt) 2005-11-22
EP1575596A1 (en) 2005-09-21
US20100298424A1 (en) 2010-11-25
CA2510051C (en) 2016-07-05
AU2003292556B2 (en) 2009-09-10

Similar Documents

Publication Publication Date Title
AR042670A1 (es) Uso del abridor del canal de cloruro para preparar un compuesto farmaceutico para tratar el malestar abdominal
AR100696A2 (es) Uso de un compuesto de 15-ceto-prostaglandina para fabricar una composición para tratar estreñimiento inducido por drogas
AR036391A1 (es) Uso de un compuesto de prostaglandina para preparar una composicion farmaceutica para abrir los canales de cic en un mamifero y compuestos de prostaglandina
CL2020000029A1 (es) Nuevos compuestos de carboxamida sulfonamida.
CO2020009225A2 (es) Análogos de dihidrobenzofurano e indeno como inhibidores del sarcómero cardíaco
AR055878A1 (es) Derivados de ciclopropanocarboxamida
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
CY1111493T1 (el) Παραγωγα πυραζολιου ως τροποποιητες πρωτεϊνοκινασης
ECSP066298A (es) Compuestos 1h-pirazol 3,4-disustituidos y su uso como moduladores de quinasas dependientes de ciclina (cdk) y quinasa-3 de sintasa de glicógeno (gsk-3)
HK1119699A1 (en) Pyridopyrimidinone inhibitors of pi3kalpha
CO6220952A2 (es) Nuevos derivados de 3-([1,2,4]triazolo[4,3-a]piridin-7-il)benzamida
AR066962A1 (es) Compuesto heterociclico fusionado
UY28141A1 (es) Nuevos derivados de piridazin-3(2h)-ona
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR055846A1 (es) Compuesto de prostaglandina y metodo para tratar trastornos del sistema nervioso central
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
AR036044A1 (es) Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma
AR044650A1 (es) Derivados de tiofeno - pirimidinona y su uso en la terapia de enfermedades que requieren la inhibicion de la enzima 17b-hidroxiesteroide-dehidrogenasa.
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
CO5031247A1 (es) Compuestos triciclicos sustituidos
NO20084516L (no) Terfenylderivater for behandling av alzheimers sykdom
AR111272A1 (es) Derivados pirazol[1,5-a]pirimidina sustituidos con arilo farmacológicamente activos
CO5660290A2 (es) 6-(1,1-difluoroalquil)-4-aminopicolinatos y su uso como herbicidas
AR060427A1 (es) Amino- derivados de androstanos y androstenos como medicamentos para los trastornos cardiovasculares
CL2021001039A1 (es) Conjugados de fármaco-anticuerpo que comprenden derivados de la ecteinascidina.

Legal Events

Date Code Title Description
FC Refusal